Division of Surgical Oncology - Annual Report 2003
ACADEMIC ANNUAL REPORT DIVISION OF SURGICAL ONCOLOGY - 2003
Submitted by: Walley J Temple, MD FRCSC FACS
Professor & Chief of Division
The Division of Surgical Oncology, Department of Oncology, University of Calgary, Foothills Medical
Centre/Tom Baker Cancer Centre continues development in its academic, service, and research
components.
Service:
We look forward to the addition of Neurosurgical Oncology.
The Hepatobilary Clinic is now established with a full hepatobiliary group within the Cancer Centre. This
has resulted in all significant hepatobiliary surgery for cancer in southern Alberta being located within the
purview of the Cancer Centre and the University of Calgary. This group has been very active in
developing a synoptic surgical record and follow-up template. They continue to accrue patients in a
prospective trial on the management of liver metastases using a preoperative or neoadjuvant
chemotherapy.
A number of new procedures continue to be introduced into the armamentarium of surgery which are
either only found in Calgary or in only a few centres throughout Canada. This includes intraperitoneal
chemotherapy for advanced colorectal disease into the peritoneum, pseudomyxoma peritonei, appendix
cancer, and other primary peritoneal tumors. It also includes the selective management of advanced
hepatic tumors utilizing radiofrequency ablation, selective hepatic portal vein ligation, and preoperative
chemotherapy. A new technique for limb perfusion has been introduced for metastatic melanoma and
other cutaneous tumors. The Endocrine Surgery Group has developed a unique team where cooperation
between Edmonton and Calgary is frequent with surgery, nuclear medicine, chemotherapy, and molecular
targets. The Endocrine Tumor Clinic is one of the few such clinics in the world and continues to make
progress on a number of rare tumors including carcinoid tumors and thyroid tumors.
Research:
The efforts of the Cancer Surgery Working Group have resulted in a submission to the
provincial government for funding for the entire province to introduce synoptic reporting for colon
cancer, breast cancer, hepatobiliary cancer, and sarcoma. The first synoptic approach will be introduced
for hepatobiliary tumors.
The quality of life study for 150 breast cancer patients, followed now for 6 years, is starting to analyze the
results. The study is almost completed.
Funding continues in many areas of research, including breast cancer, hepatobiliary, immunology, and
melanoma. We remain involved in international trials in melanoma and breast cancer. We are looking at
the electro-characteristics of breast cancer and work to date has generated a paper on the use of this
potential new diagnostic modality. Overall grant funding for our members is approximately $1.9 million.
The publications number 32 for the group for the past year with provincial, national, and international
presentations numbering 80.
Administration:
Members of the group continue to be active as President of the Canadian Society
of Surgical Oncology, as Editors of the Journal of Surgical Oncology and Seminars in Surgical Oncology,
in the Royal College Surgical Oncology Training Program Group, as Co-founder and 1st President of the
Canadian Hepato-Pancreato-Biliary Society, as Vice-Chair of the American College of Surgeons, and as
leader in the development of the Calgary Breast Program, to name some of the highlights.
Education:
Significant awards and successes have accrued in the educational area. The Surgical
Oncology Training Program is now approved by the prestigious American Society of Surgical Oncology.
We continue to train 2 residents – 1 in endocrine surgical oncology and 1 in general surgical oncology.
We continue to have General Surgery Residents rotate through our program spending increasing time in
surgical oncology to keep up with the current advances. Our members include the Chair of the University
of Calgary Surgical Oncology Training Program which is Royal College approved and Chair of the
1
Division of Surgical Oncology - Annual Report 2003
General Surgery Training Program, also Royal College approved. We continue to have our Surgical
Oncology Day and were fortunate in 2003 to have as our guest Dr Charles Balch, Executive Vice
President and CEO of ASCO. This year we look forward to having a leader in hepatobiliary surgery from
Toronto, Dr Steve Gallinger. There have been some awards to members in our division including the
Royal College of Physicians and Surgeons Mentor of the Year Award.
Overall our division has continued development in all areas and we are extremely grateful for the support
of the Alberta Cancer Board and the University of Calgary which have made this all possible.
Annual reports surg oncol tbcc 2003 academic report feb 04.doc/ldh
2
Division of Surgical Oncology - Annual Report 2003
MEMBERS - Division of Surgical Oncology
John P Arlette 403 216 4685
Fax 403 216 4689
E mail arlette@johnarlette.com
Publications
Bienert T, Trotter M, Arlette J. Malignant melanoma of the face treated with Mohs micrographic surgery.
J Cutan Med Surg 2003 Jan-Feb; 7(1):25-20.
Oliver F Bathe 403 670 2098
Fax 403 283 1651
E mail bathe@ucalgary.ca
Publications
Bathe OF, Mies C, Casillas J, Franceschi D, Liningstone AS. Massive hemorrhage and infarction
complicating focal nodular hyperplasia: Case report and literature review. HPB Surgery 2003; 5:123-126.
Bathe OF, Dalyot-Herman N, Malek RE. Therapeutic limitations in tumor-specific CD8+ Memory T cell
engraftment. BMC Cancer 2003; 3:21.
Grants
Tumor immunity vs autoimmunity following cellular immunotherapy
Source: American College of Surgeons (Faculty Research Award)
Awarded: $US 40,000/year
Dates of Approved Project: July 2003 – July 2004
Name of PI: Oliver F. Bathe
Tumor immunity as a function of autoimmunity
Source: Cancer Research Society
Awarded: $60,000/year
Dates of Approved Project: September 2003 – September 2005
Name of PI: Oliver F. Bathe
Refining the ‘danger’ hypothesis in the context of the immune response against tumor
Source: University of Calgary Department of Surgery Young Faculty Research Award
Awarded: $75,000
Dates of Approved Project: September 2003 – September 2004
Name of PI: Oliver F. Bathe
Neoadjuvant 5-FU + leucovorin + CPT-11 for liver metastases from colorectal adenocarcinoma
Source: Pfizer Canada Inc
Awarded: $308,000
Dates of Approved Project: 2003 – 2006
PI: Oliver F. Bathe
A Phase III double-blind multi-centre randomized study in chemo-naïve patients with locally advanced or
metastatic pancreatic cancer to compare a combination therapy of virulizin + gemcitabine + placebo vs
placebo + gemcitabine
Source: Lorus Therapeutics Inc
Awarded: $9,743.50/patient
Dates of Approved Project: ongoing
Name of PI: Oliver F. Bathe
3
Division of Surgical Oncology - Annual Report 2003
W Donald Buie
403 670 2020
Fax 403 8004
E mail wdbuie@ucalgary.ca
Publications
Topstad DR, Panaccione R, Johnson JA, MacLean AR, Buie WD. Combined seton placement, infliximab
infusion and maintenance. Dis Colon & Rectum 2003 May; 46(5):577-83.
Grants
Opioid-induced postoperative ileus
Adalor Corporation
$3,800/patient
Anastomosis trail for Crohn’s disease
Crohn’s & Colitis Foundation
$1,000/patient
Perioperative stress dose steroids
CHR/Department of Surgery
$7,460
Pathology-guided treatment in rectal cancer
National Cancer Institute of Canada
$1,700/patient
Remicade for perianal Crohn’s
CHR/Department of Surgery/Foothills Medical Centre
PI
Outbreak of clostridium difficile colitis caused by clindamycin-resistant strain associated with increased
rate of surgical intervention
CHR/Department of Surgery/Foothills Medical Centre
PI
Hypoxia and anastomotic leaking
CHR/Department of Surgery/Foothills Medical Centre
Co-Investigator
Timing of rectal cancer – Response to chemoradiation
NIH
$200,000/$30,000
PI
5-year Provincial outcomes following resection for rectal cancer
Cancer Surgery Working Group, Alberta Cancer Board
PI
$12,000
Scoring system for anastomotic leak
CHR/Department of Surgery/Foothills Medical Centre
Co-investigator
Incontinence following chemoradiation for rectal cancer
CHR/Department of Surgery/Foothills Medical Centre
Co-investigator
Portal venous thrombosis following ileopouch procedure
4
Division of Surgical Oncology - Annual Report 2003
CHR/Department of Surgery/Foothills Medical Centre
Co-investigator
Colonoscopy surveillance following resection for colorectal cancer
CHR/Department of Surgery/Foothills Medical Centre
Co-investigator
Late recurrence following curative resection
CHR/Department of Surgery/Foothills Medical Centre
PI
William G de Haas
Elijah Dixon
403 571 3150
403 944 8323
Fax 403 571 3133
Fax 403 283 1651
E mail elijah.dixon@calgaryhealthregion.ca
Publications
Dixon E, Vollmer Jr CM, Greig PD, Gallinger S. HPB Clinics around the world- The University of
Toronto HPB program at the Toronto General Hospital. HPB 2003; 5(1):39-42.
Vollmer CM, Dixon E, Sahajpal A, Cattral MS, Grant DR, Taylor BR, Gallinger S, Greig PD. Abstract –
Extended hepatic resections-increased risk with biliary resection and reconstruction. J Gastrointest Surg
2003 Feb; 7(2)L282-283.
Vollmer CM, Dixon E, Guindi M, Grant DR, Cattral MS, Gallinger S, Greig PD. Abstract – Ablation of
hepatocellular carcinoma (HCC) prior to transplantation-pathologic analysis of the explant. J Gastrointest
Surg 2003 Feb; 7(2):266.
Sutherland F, Dixon E, Bathe O, Anderson M. Abstract – Anatomic studies of the hepatocaval ligament. J
Gastrointest Surg 2003 Feb; 7(2).280.
Dixon E, Sutherland FR, Vollmer Jr CM, Greig PD. Bile duct injury following laparoscopic
cholecystectomy: Resection of the entire extrahepatic/pancreatic tree. J American College of Surgeons
2003 Nov; 197(5):862-863.
Grants
The effect that the presence of liver transplantation programs and comprehensive cancer centers have on
patient outcome following liver resection in the United States.
Centre for the Advancement of Health, Calgary
$7,500.00
Joseph C Dort 403 220 4307
Fax 403 220 3145
E mail jdort@ucalgary.ca
Publications
Sywak M, Pasieka JL, McFadden S, Gelfand G, Terrell J, Dort J.Functional results and quality of life fter
tracheal resection for locally invasive thyroid cancer. Am J Surg 2003; 185:462-4767.
Lobay K, Dort J. Varaztad Kazanjian: Life and time. Proceedings of the History of Medicine Days
Journal. 2003; 135-140.
Grants
Alberta Health & Wellness Health Innovation Fund
Operating Grant
5
Division of Surgical Oncology - Annual Report 2003
2003
Universal Newborn Hearing Screening Program in Alberta
Principal Investigator
Awarded $143,000
Private donation - $25,000
Private donation - $200,000
Gary A J Gelfand
403 944 4268
Fax 403 270 8431
E mail gelfand@ucalgary.ca
Publications
Sywak M, Pasieka JL, McFadden S, Gelfand G, Terrell J, Dort J.Functional results and quality of life fter
tracheal resection for locally invasive thyroid cancer. Am J Surg 2003; 185:462-4767.
Rene Lafreniere
403 944 1697
Fax 403 270 8409
E mail rlafreni@telusplanet.net
Publications
Lafrenière R. Ethical issues in surgical treatment and research. Curr Probl Surg 2003 Jul; 40(7):353-448.
Grants
Alberta Cancer Board RIP Grant
Institute for Health Economics
Anonymous Donor
Total for reporting year - $342,360
Robert L Lindsay
Enzio Magi
403 571 3155
403 571 3130
Sean McFadden
Fax 403 3138
Fax 403 571 3133
403 944 4268 Fax 403 270 8431
E mail sean.mcfadden@calgaryhealthregion.ca
Publications
Sywak M, Pasieka J, McFadden S, Gelfand G, Terrell, Dort J. Functional results and quality of life
following tracheal resection for locally invasive thyroid cancer. Am J Surg 2003; 185:462-467.
Kneafsey P, Duggan M, McFadden S. Fine needle aspiration cytology of pulmonary, well-differentiated
fetal adenocarcinoma prepared by the ThinPrep® method. Cytopathology 2003; 14:87-90.
Grants
NCIC-BR 19 – A Phase III prospective randomized, double-blind, placebo-controlled trial of the
epidermal growth factor receptor antagonist, ZD 1839 (IRESSA) in completely resected primary Stage
IB, II, IIIA non-small cell lung cancer.
Local principal investigator
6
Division of Surgical Oncology - Annual Report 2003
J Gregory McKinnon 403 944 2844
Fax 403 283 1651
E mail mckinnon@ucalgary.ca
Publications
Li LL, Scolyer RA, Ka VSK, McKinnon JG, Shaw HM, McCarthy SW, Thompson JF. Pathologic
review of negative sentinel lymph nodes in melanoma patients with regional recurrence: A
clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Surg Path. 2003;
27(9):1197-1202.
McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous
melanoma: Long-term survival data from the New South Wales Central Cancer Registry and the Sydney
Melanoma Unit. Cance. 2003 Sep 15; 98(6):1223-31.
Thompson SK, McKinnon JG, Ghali WA. Perioperative stroke occurring in patients who undergo neck
dissection for head and neck cancer: Unanswered questions. Can J Surg 2003; 46(5):332-334.
Daphne JY Mew MD 403 220 2859
Fax 403 283 4841
E mail dmew@ucalgary.ca
Grants
Preoperative PET Imaging in Breast Cancer Patients: Correlation with Histologic Findings of Sentinel
Node Biopsies and Axillary Dissection (Drs. D. Severin, D. Mew)
Alberta Cancer Board
$100,926.60
Ongoing
Co-investigator.
Micrometastasis in Bone Marrow of Patients Undergoing Primary Surgery for Newly-Diagnosed Breast
Cancer (Drs S. Gluck, A. Magliocco and D. Mew)
$99,412
Ongoing
Co-investigator.
Janice L Pasieka MD 403 944 2491 Fax 403 283 4130
E mail janice.pasieka@calgaryhealthregion.ca
Publications
Sywak M, Romano C, Raber E, Pasieka JL. Septic thrombophlebitis of the inferior mesenteric vein from
sigmoid diverticulitis. J Am College of Surgeons 2003; 196(2):326-327.
Pasieka JL. Anaplastic thyroid cancer. Current Opinion in Oncology. 2003; 15(1):78-83.
Pasieka JL. Surgical approach to secondary hyperparathyroidism. Problems in General Surgery. 2003;
20(3):61-67.
Sywak M, Pasieka JL, McFadden S, Gelfand G, Terrell J, Dort J.Functional results and quality of life
fter tracheal resection for locally invasive thyroid cancer. Am J Surg 2003; 185:462-4767.
Pasieka JL. Asymptomatic primary hyperthyroidism: Standards and guidelines for diagnosis and
management in Canada. Endocrine Practice 2003; 9(5):400-405.
Norman S Schachar MD
403 220 2880 Fax 403 270 3927
E mail nsschach@ucalgary.ca
Grants
Osteochondral Transplantation for Repair of Joint Surface Injury
7
Division of Surgical Oncology - Annual Report 2003
Canadian Institute of Health Research
Awarded: $359, 806
Dates of approved project: 2002 – 2006
Principal investigator
Francis R Sutherland
403 944 8323 Fax 403 283 1651
E mail francis.sutherland@calgaryhealthregion.ca
Publications
Ashton J, Sutherland F, Nixon J, Nayak V. A case of solid pseudopapillary tumor of the pancreas:
Preoperative cyst fluid analysis and treatment by enucleation. Hepatogastroenterology 2003; 50:22392241.
Sutherland F, Cunningham J, Pontikes L, Parsons L, Klassen J. Elevated serum interleukin 6 levels in
patients with acute intestinal ischemia. Hepatogastroenterology 2003; 50:419-421.
Qin H, Goldstein L, Iwanicki S, Mackay E, Sutherland F. Hyperlipemic pancreatitis and pseudocyst
formation in late pregnancy. Hepatogastroenterology 2003; 50:870-872.
Cooke M, Dunham M, Sutherland F. Soft tissue images: Proximal gastrointestinal stromal tumor. Can J
Surg 2003; 46:121-122.
McCullough L, Sutherland F, Preshaw R. Gallstone pancreatitis: Does discharge and readmission affect
outcome. HPB2003; 5:96-99.
Medlicott S. Beaudry P, Morris G, Hollaar G, Sutherland F. Intestinal thromboangitis obliterans in a
woman: A case report and discussion of chronic ischemic changes. Can J Gastroenterol 2003; 17:559561.
Dixon E, Sutherland FR, Vollmer Jr CM, Greig PD. Bile duct injury following laparoscopic
cholecystectomy: Resection of the entire extrahepatic/pancreatic tree. J American College of Surgeons
2003 Nov; 197(5):862-863.
Walley J Temple MD
403 944 1914 Fax 403 283 1651
E mail walleyte@cancerboard.ab.ca
Publications
Sampath S, Temple CL, Temple WJ. Precision handling of the sentinel node. J Surg Oncol 2003;
84(3):176-7.
Temple WJ. Editorial – Global issues in surgical oncology. J Surg Oncol 2003. 83:61.
Grants
Multicenter Selective Lymphadenectomy Trial (MSLT).
John Wayne Cancer Centre/ NIH –
$US 21,000 + 1,450/patient accrued
Ongoing
Co-investigator
Phase III randomized double-blind pivotal trial of immunotherapy with BCG plus a polyvalent melanoms
vaccine, CancerVaxSYMBOL 227\f”Symbol”\s 10 versus BCG plus a placebo as a post-surgical
treatment for Stage III and Stage IV melanoma.
Cancer Vax Vaccine Corp/National Institute of Health
$US 6,000/Stage III patient, $2,305/Stage IV patient accrued
Ongoing
8
Division of Surgical Oncology - Annual Report 2003
Co-investigator
Alberta Cancer Foundation. Visiting scholar grant. Support to bring international speaker as guest to
annual Surgical Oncology Symposium - $3,000
Johnson & Johnson. Educational grant. Support for annual Surgical Oncology Symposium - $500
Novartis Pharma Canada Inc. Educational grant. Support for annual Surgical Oncology Symposium $500
Partners in Health/ATCO Surgical Oncology Fund. Research operating continuation grant to support
breast cancer study - $27,220.
Schering Canada. Educational grant. Support for annual Surgical Oncology Symposium - $3500
Private donation from family to Richardson Surgical Oncology Fund. Research Grant. $5,000
Private donations from cancer patients/families for cancer research support - $1,000
Private donation from ATCO Group to surgical oncology through Alberta Cancer Foundation - $25,000
Annual reports surg oncol tbcc 003 academic report feb 04.doc/ldh
9